Key statistics dashboard for Nyxoah S.A. (NYXH). Valuation multiples (P/E, P/B, EV/EBITDA), profitability margins, financial-health ratios, per-share metrics and stock-level data in one consolidated view — the snapshot quantitative analysts and value investors check first.
Nyxoah SA, a medical technology company, develops and commercializes solutions to treat obstructive sleep apnea (OSA). The company’s lead solution comprises Genio system, a CE-Marked, patient-centric, minimally invasive, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea. Nyxoah SA was incorporated in 2009 and is headquartered in Mont-Saint-Guibert, Belgium.
Stock Data
| Price | $1.49 |
| Market Cap | $149M |
| Enterprise Value | $123.6M |
| Beta | 0.87 |
| Exchange | NASDAQ |
| Country | BE |
Valuation Multiples
| P/E Ratio | -0.60 |
| Price / Book | 0.89 |
| P/S | 5.73 |
| EV/EBITDA | -1.60 |
| EV/Sales | 5.45 |
| EV/FCF | -1.67 |
| P/FCF | -1.76 |
| Earnings Yield | -127.94% |
| FCF Yield | -54.67% |
| Dividend Yield | 0.00% |
Profitability
| Gross Margin | 51.31% |
| EBIT Margin | -362.82% |
| EBITDA Margin | -341.10% |
| Operating Margin | -383.05% |
| Net Margin | -434.72% |
| Return on Equity | -179.71% |
| Return on Assets | -58.46% |
| Return on Invested Capital | -59.89% |
| Return on Capital Employed | -71.60% |
Financial Health
| Current Ratio | 2.38 |
| Quick Ratio | 2.31 |
| Cash Ratio | 1.36 |
| Debt / Equity | 0.63 |
| Debt / Assets | 31.20% |
| Net Debt / EBITDA | 0.15 |
| Interest Coverage | -5.73 |
Per-Share Data
| Revenue per share | 0.40 |
| Book Value per share | 1.46 |
| Cash per share | 1.72 |
| FCF per share | -1.30 |
| Tangible Book Value per share | 0.62 |
| Dividend per share | 0.00 |
Related companies: CATX · GNFT · IVVD · KRMD · OABI · OSUR · PRE
Explore sector: Healthcare · Medical - Specialties
More sections of NYXH: Overview · Financials · Valuation · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks